Patents by Inventor Leslie D. Cope
Leslie D. Cope has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140147461Abstract: The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1 and uses of such polypeptides and compositions thereof. SEQ ID NO: 1 is a full length S. aureus sequence. A derivative of SEQ ID NO: 1 containing an amino terminus his-tag was found to produce a protective immune response against S. aureus.Type: ApplicationFiled: February 7, 2014Publication date: May 29, 2014Applicant: Merck Sharp & Dohme Corp.Inventors: Tessie B. McNeely, Leslie D. Cope, Mark A. Miller, Loren D. Schultz, Xinmin Wang
-
Publication number: 20110229508Abstract: The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1 and uses of such polypeptides and compositions thereof. SEQ ID NO: 1 is a full length S. aureus sequence. A derivative of SEQ ID NO: 1 containing an amino terminus his-tag was found to produce a protective immune response against S. aureus.Type: ApplicationFiled: November 18, 2009Publication date: September 22, 2011Inventors: Tessie B. McNeely, Leslie D. Cope, Mark A. Miller, Loren D. Schultz, Xinmin Wang
-
Publication number: 20110229509Abstract: Disclosed are polypeptides comprising an amino acid sequence structurally related to SEQ ID NO 1 and uses of such polypeptides and compositions thereof. SEQ ID NO 1 is a full length S. aureus sequence. A derivative of SEQ ID NO 1 containing an amino terminal his-tag was found to produce a protective immune response against S. aureus.Type: ApplicationFiled: November 18, 2009Publication date: September 22, 2011Inventors: Tessie B. McNeely, Leslie D. Cope, Mark A. Miller, Loren D. Schultz, Xinmin Wang
-
Publication number: 20110091480Abstract: The present invention features antigen binding protein that bind an ORF0657n target region (SEQ ID NO: 1). ORF0657n is an S. aureus protein. ORF0657n target regions are provided by the mAb 1G3.BD4, mAb 2H2.BE11, mAb 13C7.BC1, and mAb 13G11.BF3 binding sites. In a lethal model challenge, mAb 2H2.BE11 and mAb 13C7.BC1 provided for increased survival against S. aureus infection. There was also protection demonstrated in an ex vivo model with either the IgG1 or the IgG2b form of mAb 2H2; and in a passive immunization murine indwelling catheter model using mAb 2H2.BE11.Type: ApplicationFiled: January 23, 2007Publication date: April 21, 2011Inventors: Martha J. Brown, Annaliesa S. Anderson, Leslie D. Cope, Kathrin Ute Jansen, Tessie McNeely, Barrett R. Harvey, Eberhard Durr, Robin Ernst
-
Publication number: 20100166772Abstract: The present invention features antigen binding proteins that bind to a region found to have an epitope that can be targeted to provide protection against S. aureus infection. The region is designated herein as the “CS-D7” target region. The CS-D7 target region provides an S. aureus ORF0657n epitope that can be targeted to reduce the likelihood or severity of an S. aureus infection.Type: ApplicationFiled: May 29, 2008Publication date: July 1, 2010Inventors: Annaliesa S. Anderson, Desmond J. Clark, Zhiqiang An, Fubao Wang, Susan L. Secore, Eberhard Durr, Leslie D. Cope, Tessie McNeely
-
Patent number: 7576194Abstract: The present invention discloses the existence of two novel proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2. Each protein encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by the MAb 17C7. One or more than one of these species may aggregate to form the very high molecular weight form (i.e. greater than 200 kDa) of the UspA antigen. Compositions and both diagnostic and therapeutic methods for the treatment and study of M. catarrhalis are disclosed.Type: GrantFiled: March 7, 2008Date of Patent: August 18, 2009Assignee: Board of Regents, The University of Texas SystemInventors: Eric J. Hansen, Christoph Aebi, Leslie D. Cope, Isobel Maciver, Michael J. Fiske, Ross A. Fredenburg
-
Patent number: 7569683Abstract: The present invention discloses the existence of two novel proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2. Each protein encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by the MAb 17C7. One or more than one of these species may aggregate to form the very high molecular weight form (i.e. greater than 200 kDa) of the UspA antigen. Compositions and both diagnostic and therapeutic methods for the treatment and study of M. catarrhalis are disclosed.Type: GrantFiled: March 7, 2008Date of Patent: August 4, 2009Assignees: Board of Regents, The University of Texas System, Wyeth Holding CorporationInventors: Eric J. Hansen, Christoph Aebi, Leslie D. Cope, Isobel Maciver, Michael J. Fiske, Ross A. Fredenburg
-
Publication number: 20090137788Abstract: The present invention discloses the existence of two novel proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2. Each protein encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by the MAb 17C7. One or more than one of these species may aggregate to form the very high molecular weight form (i.e. greater than 200 kDa) of the UspA antigen. Compositions and both diagnostic and therapeutic methods for the treatment and study of M. catarrhalis are disclosed.Type: ApplicationFiled: March 7, 2008Publication date: May 28, 2009Inventors: ERIC J. HANSEN, Christoph Aebi, Leslie D. Cope, Isobel Maciver, Michael J. Fiske, Ross A. Fredenburg
-
Publication number: 20090118486Abstract: The present invention discloses the existence of two novel proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2. Each protein encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by the MAb 17C7. One or more than one of these species may aggregate to form the very high molecular weight form (i.e. greater than 200 kDa) of the UspA antigen. Compositions and both diagnostic and therapeutic methods for the treatment and study of M. catarrhalis are disclosed.Type: ApplicationFiled: March 7, 2008Publication date: May 7, 2009Inventors: ERIC J. HANSEN, Christoph Aebi, Leslie D. Cope, Isobel Maciver, Michael J. Fiske, Ross A. Fredenburg
-
Patent number: 7344724Abstract: The present invention discloses the existence of two novel proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2. Each protein encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by the MAb 17C7. One or more than one of these species may aggregate to form the very high molecular weight form (i.e. greater than 200 kDa) of the UspA antigen. Compositions and both diagnostic and therapeutic methods for the treatment and study of M. catarrhalis are disclosed.Type: GrantFiled: June 21, 2004Date of Patent: March 18, 2008Assignees: Board of Regents, The University of Texas System, Wyeth Holdings CorporationInventors: Eric J. Hansen, Christoph Aebi, Leslie D. Cope, Isobel Maciver, Michael J. Fiske, Ross A. Fredenburg
-
Patent number: 7288646Abstract: The present invention discloses the existence of two novel proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2. Each protein encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by the MAb 17C7. One or more than one of these species may aggregate to form the very high molecular weight form (ie. greater than 200 kDa) of the UspA antigen. Compositions and both diagnostic and therapeutic methods for the treatment and study of M catarrhalis are disclosed.Type: GrantFiled: June 21, 2004Date of Patent: October 30, 2007Assignee: Board of Regents, The University of Texas SystemInventors: Eric J. Hansen, Christoph Aebi, Leslie D. Cope, Isobel Maciver, Michael J. Fiske, Ross A. Fredenburg
-
Patent number: 7157443Abstract: A high molecular weight polysaccharide intracellular adhesin (SAE) antigen having the general structure of poly-1,6,?-2-amidoglucopyranoside, which is variable substituted with N-acetyl and O-succinyl substituents is described. Also, a method is given for isolating this antigen from Staphylococcus aureus. The SAE can be used in a vaccine, either alone, conjugated to an immunogenic protein, and/or with an immunogenic adjuvant.Type: GrantFiled: December 6, 2002Date of Patent: January 2, 2007Assignee: Merck & Co., Inc.Inventors: Joseph G. Joyce, James C. Cook, III, Chitrananda Abeygunawardana, Karen M. Grimm, Craig T. Przysiecki, Robert W. Hepler, Charlotte C. Ip, Keith Roper, Qiuwei Xu, Kathrin U. Jansen, Paul M. Keller, Leslie D. Cope
-
Publication number: 20040259838Abstract: A high molecular weight polysaccharide intracellular adhesin (SAE) antigen having the general structure of poly-1,6,&bgr;-2-amidoglucopyranoside, which is variable substituted with N-acetyl and O-succinyl substituents is described. Also, a method is given for isolating this antigen from Staphylococcus aureus. The SAE can be used in a vaccine, either alone, conjugated to an immunogenic protein, and/or with an immunogenic adjuvant.Type: ApplicationFiled: June 9, 2004Publication date: December 23, 2004Inventors: Joseph G. Joyce, James C. Cook III, Chitrananda Abeygunawardana, Karen M. Grimm, Craig T. Przysiecki, Robert W. Hepler, Charlotte C. Ip, Donald Keith Roper, Qi Wei Xu, Kathrin U. Jansen, Paul M. Keller, Leslie D. Cope
-
Patent number: 6753417Abstract: The present invention discloses the existence of two novel proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2. Each protein encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by the MAb 17C7. One or more than one of these species may aggregate to form the very high molecular weight form (i.e. greater than 200 kDa) of the UspA antigen. Compositions and both diagnostic and therapeutic methods for the treatment and study of M. catarrhalis are disclosed.Type: GrantFiled: September 12, 2001Date of Patent: June 22, 2004Assignees: Board of Regents, The University of Texas System, American Cyanamid CompanyInventors: Eric J. Hansen, Christoph Aebi, Leslie D. Cope, Isobel Maciver, Michael J. Fiske, Ross A. Fredenburg
-
Publication number: 20030032772Abstract: The present invention discloses the existence of two novel proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2. Each protein encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by the MAb 17C7. One or more than one of these species may aggregate to form the very high molecular weight form (i.e. greater than 200 kDa) of the UspA antigen. Compositions and both diagnostic and therapeutic methods for the treatment and study of M. catarrhalis are disclosed.Type: ApplicationFiled: September 12, 2001Publication date: February 13, 2003Applicant: The Board of Regents, University of Texas SystemInventors: Eric J. Hansen, Christoph Aebi, Leslie D. Cope, Isobel Maciver, Michael J. Fiske, Ross A. Fredenburg
-
Patent number: 6310190Abstract: The present invention discloses the existence of two novel proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2. Each protein encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by the MAb 17C7. One or more than one of these species may aggregate to form the very high molecular weight form (i.e. greater than 200 kDa) of the UspA antigen. Compositions and both diagnostic and therapeutic methods for the treatment and study of M. catarrhalis are disclosed.Type: GrantFiled: June 21, 1999Date of Patent: October 30, 2001Assignees: Board of Regents, The University of Texas, American CyanamidInventors: Eric J. Hansen, Christoph Aebi, Leslie D. Cope, Isobel Maciver, Michael J. Fiske, Ross A. Fredenburg
-
Patent number: 6020154Abstract: Disclosed are hxuB and hxuC genes and DNA segments from H. influenzae such as H. influenzae type b (Hib) and nontypeable H. influenzae (NTHI). The HxuB and HxuC proteins, being surface expressed, are contemplated for use in the preparation of vaccines against pathological H. influenzae infections, and in particular, vaccines for use in children and other individuals who respond poorly to capsular-based vaccines. DNA segments encoding these proteins and anti- HxuB and HxuC antibodies will also be of in various screening, diagnostic and therapeutic applications.Type: GrantFiled: April 20, 1995Date of Patent: February 1, 2000Assignee: Board of Regents, The University of Texas SystemInventors: Eric J. Hansen, Leslie D. Cope, Gregory P. Jarosik, Mark S. Hanson